These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25164472)

  • 1. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
    Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
    J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
    Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
    Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
    Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
    Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
    Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
    Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
    Kourlaba G; Rapti V; Alexopoulos A; Relakis J; Koumakis G; Chatzikou M; Maniadakis N; Georgoulias V
    BMC Health Serv Res; 2015 Aug; 15():307. PubMed ID: 26239115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
    Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
    Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
    Campone M; Beck JT; Gnant M; Neven P; Pritchard KI; Bachelot T; Provencher L; Rugo HS; Piccart M; Hortobagyi GN; Nunzi M; Heng DY; Baselga J; Komorowski A; Noguchi S; Horiguchi J; Bennett L; Ziemiecki R; Zhang J; Cahana A; Taran T; Sahmoud T; Burris HA
    Curr Med Res Opin; 2013 Nov; 29(11):1463-73. PubMed ID: 23962028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
    Burris HA; Lebrun F; Rugo HS; Beck JT; Piccart M; Neven P; Baselga J; Petrakova K; Hortobagyi GN; Komorowski A; Chouinard E; Young R; Gnant M; Pritchard KI; Bennett L; Ricci JF; Bauly H; Taran T; Sahmoud T; Noguchi S
    Cancer; 2013 May; 119(10):1908-15. PubMed ID: 23504821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
    Piccart M; Hortobagyi GN; Campone M; Pritchard KI; Lebrun F; Ito Y; Noguchi S; Perez A; Rugo HS; Deleu I; Burris HA; Provencher L; Neven P; Gnant M; Shtivelband M; Wu C; Fan J; Feng W; Taran T; Baselga J
    Ann Oncol; 2014 Dec; 25(12):2357-2362. PubMed ID: 25231953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
    Beck JT; Hortobagyi GN; Campone M; Lebrun F; Deleu I; Rugo HS; Pistilli B; Masuda N; Hart L; Melichar B; Dakhil S; Geberth M; Nunzi M; Heng DY; Brechenmacher T; El-Hashimy M; Douma S; Ringeisen F; Piccart M
    Breast Cancer Res Treat; 2014 Feb; 143(3):459-67. PubMed ID: 24362951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.
    Generali D; Venturini S; Rognoni C; Ciani O; Pusztai L; Loi S; Jerusalem G; Bottini A; Tarricone R
    Breast Cancer Res Treat; 2015 Jul; 152(1):95-117. PubMed ID: 26044370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
    Cazzaniga ME; Airoldi M; Arcangeli V; Artale S; Atzori F; Ballerio A; Bianchi GV; Blasi L; Campidoglio S; Ciccarese M; Cursano MC; Piezzo M; Fabi A; Ferrari L; Ferzi A; Ficorella C; Frassoldati A; Fumagalli A; Garrone O; Gebbia V; Generali D; La Verde N; Maur M; Michelotti A; Moretti G; Musolino A; Palumbo R; Pistelli M; Porpiglia M; Sartori D; Scavelli C; Schirone A; Turletti A; Valerio MR; Vici P; Zambelli A; Clivio L; Torri V; ;
    Breast; 2017 Oct; 35():115-121. PubMed ID: 28711793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
    Rugo HS; Pritchard KI; Gnant M; Noguchi S; Piccart M; Hortobagyi G; Baselga J; Perez A; Geberth M; Csoszi T; Chouinard E; Srimuninnimit V; Puttawibul P; Eakle J; Feng W; Bauly H; El-Hashimy M; Taran T; Burris HA
    Ann Oncol; 2014 Apr; 25(4):808-815. PubMed ID: 24615500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
    Im YH; Karabulut B; Lee KS; Park BW; Adhav A; Cinkir HY; Abdel-Razeq H; Chang YC; Aksoy S; Im SA; Jeong J; Chae Y; Bowles J; Slimane K; Xue H; Kim SB
    Breast Cancer Res Treat; 2021 Jul; 188(1):77-89. PubMed ID: 33728524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.
    Cook MM; Al Rabadi L; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    Oncologist; 2021 Feb; 26(2):101-106. PubMed ID: 33230905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
    Decker T; Söling U; Hahn A; Maintz C; Kurbacher CM; Vehling-Kaiser U; Sent D; Klare P; Hagen V; Chiabudini M; Falkenstein J; Indorf M; Runkel E; Potthoff K
    BMC Cancer; 2020 Apr; 20(1):286. PubMed ID: 32252684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
    Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
    Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
    Diaby V; Adunlin G; Zeichner SB; Avancha K; Lopes G; Gluck S; Montero AJ
    Breast Cancer Res Treat; 2014 Sep; 147(2):433-41. PubMed ID: 25012857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.